Refractory Celiac Disease New Diagnostic Approaches and Current Treatment

Michael Schumann^1, , Christian Bojarski¹, Verena Moos¹ and Severin Daum¹

¹Medizinische Klinik für Gastroenterologie, Infektiologie und Rheumatologie, Charité, Campus Benjamin Franklin, Berlin, Germany

Cite this paper:
Michael Schumann, Christian Bojarski, Verena Moos and Severin Daum. Refractory Celiac Disease New Diagnostic Approaches and Current Treatment. International Journal of Celiac Disease. 2014; 2(1):33-37. doi: 10.12691/ijcd-2-1-10

Abstract

Since refractory celiac disease (RCD) may cause severe complications and is associated with a poor prognosis in a portion of patients, early diagnosis and treatment is of importance. Current diagnostics include complex PCR-based molecular pathology and FACS techniques in order to differentiate type I and type II RCD, the latter being associated with the development of an enteropathy-associated T cell lymphoma (EATL). Recently established treatment options also include high-dose chemotherapeutic regimens for RCD type II which have significantly improved survival. However, treatment strategies are highly individual targeting also complications of malabsorption and should be started in the RCD phase of the disease. Therefore, adequate diagnostics are pivotal for patient outcome.

Keywords:

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

Figures

References:

[1]	West J et al., Gastroenterology 2009; 136(1): 32-34.
[2]	Roshan B et al., Am J Gastroenterol2011; 106(5): 923-928.
[3]	CellierC et al., Lancet. 2000; 356(9225): 203-208.
[4]	Nijeboer P et al., Gastroenterol Res Pract. 2013; 518483.
[5]	Rubio-Tapia et al., Gut. 2010; 59(4): 547-557.
[6]	Abdulkarim et al., Am J Gastroenterol.2002; 97(8): 2016-2021.
[7]	Daum S et al., Clin Gastroenterol Hepatol 2006; 4(10): 1232-1236.
[8]	Vakiani E et al., Mod Pathol. 2010 Jan; 23(1):12-26.
[9]	Caruso R et al., Clin Sci (Lond). 2014; 126(6): 451-458.
[10]	Sarra et al., Mucosal Immunol. 2013; 6(2): 244-255.
[11]	Holmes GK et al., Gut. 1989; 30(3): 333-8.
[12]	Schumann M et al., Ann N Y AcadSci. 2012 Jul;1258:43-51
[13]	Daum S et al., Eur J Gastroenterol Hepatol. 2009; 21(1): 66-70.
[14]	Mention JJ et al., Gastroenterology. 2003; 125(3): 730-745.
[15]	Malamut G et al., Gastroenterology. 2009;136(1):81-90.
[16]	Malamut G et al., J Clin. Invest. 2010; 120(6): 2131.
[17]	Van Heel et al., Nat Genet. 2007;39(7): 827-829.
[18]	HueS et al., Immunity 2004; 21: 367-377.
[19]	Schmitz et al., Gut 2013; 62: 509-519.
[20]	Malamut et al., SeminImmunopathol 2012; 34: 601-613.
[21]	Verbeek et al., Clinical Immunology 2008; 126: 48-56.
[22]	Tjon et al., Blood 2012; 112(13): 5103-5110.
[23]	Daum S et al., Gut 2001; 49(6): 804-812.
[24]	Liu H et al., Gut 2010; 59: 452-460.
[25]	Verkarre V et al., Gut 2003; 52(2): 205-211.
[26]	Verbeek WH et al., Clinical Immunology 2008; 126, 48-56.
[27]	Cellier C et al., Gastroenterology 1998; 114(3): 471-481.
[28]	Stijn et al., Radiology2011; 259(1): 151-161.
[29]	Daum S et al., Endoscopy 2007; 39(5): 455-458.
[30]	Collin P et al., J Dig Dis. 2012; 13(2): 94-99.
[31]	Barret et al., Am J Gastroenterol. 2012; 107(10): 1546-1553.
[32]	Hadithi et al., Am J Gastroenterol. 2007; 102(5): 987-996.
[33]	Malamut G et al., Gastroenterology 2009; 136: 81-90.
[34]	Rubio-Tapia A et al., Gastroenterology 2009; 136(1): 99-107.
[35]	Daum S et al., Digestion 2006; 73(1): 60-68.
[36]	Goerres MS et al., Aliment Pharmacol Ther. 2003; 18(5): 487-494.
[37]	JammaS et al., J Clin Gastroenterol 2010; 45(1): 30-33.
[38]	Tack GJ et al., Aliment Pharmacol Ther. 2012; 36(3): 274-281.
[39]	Tack GJ et al., Bone Marrow Transplant 2011; 46(6): 840-846.